Follow the news, literature, and elearning on new developments in the management of Heart Failure.
The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.
ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.
Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.
ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.
Impaired coronary microvascular function is highly prevalent in HFpEF patients and is associated with high levels of natriuretic peptides, systemic endothelial dysfunction, and cardiac dysfunction.
ESC 2018 The TRANSITION study results show that sacubitril/valsartan was safe and well-tolerated in a wide range of HFrEF patients who have been stabilized after an acute HF episode , showing CV safety.
ESC 2018 In the COMMANDER-HF study, rivaroxaban did not significantly reduce CV mortality and morbidity in HFrEF patients with CAD with recent decompensation.
Studies in mice and humans suggest that heart failure is associated with enhanced tumor growth, independent of hemodynamic impairment, and may be caused by secretion of cardiac factors.
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.
In patients with chronic kidney disease, sacubitril/valsartan had similar effects on renal function compared with irbesartan after 12 months of therapy. ARNI therapy did lower BP, NT-proBNP and troponin.
Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.
Prof. Sattar looked at the data of recent outcome trials to postulate how they might work to exert the observed clinical benefit. Altered hemodynamics likely importantly contribute to the benefits on HF outcomes.